Atlas Trials

Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study

Clinical trial NCT05556291 · COMPLETED

Trial details

NCT number
NCT05556291
Sponsor
Getz Pharma
Status
COMPLETED
Study type
OBSERVATIONAL
EfficacySafetyTolerability
Start date
2022-12-01
Primary completion
2024-07-01
Enrollment
190

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.